Neill Moray Mackenzie, Biotecnol: Immunotherapies for Life™




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Neill Moray Mackenzie, Biotecnol: Immunotherapies for Life™
Released on: September 11, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Biotecnol is working in the field of immuno-oncology and is using proprietary antibody-based technologies to engineer and develop highly- targeted therapeutic products which utilize a patient’s own immune system to fight cancer.
  • Summary
  • Transcript
  • Participants
  • Company
Biotecnol is working in the field of immuno-oncology and is using proprietary antibody-based technologies to engineer and develop highly- targeted therapeutic products which utilize a patient’s own immune system to fight cancer. Neil Moray McKenzie talks to Fintan Walton, CEO of PharmaVentures about how they are exploiting the exclusive rights to the Tribody™ format, a proprietary technology that harbors the potential to engineer the next generation of antibody-based therapeutics.
Biotecnol is working in the field of immuno-oncology and is using proprietary antibody-based technologies to engineer and develop highly- targeted therapeutic products which utilize a patient’s own immune system to fight cancer. Neil Moray McKenzie talks to Fintan Walton, CEO of PharmaVentures about how they are exploiting the exclusive rights to the Tribody™ format, a proprietary technology that harbors the potential to engineer the next generation of antibody-based therapeutics.
Biotecnol
Biotecnol